Zoetis Inc. Files 8-K: Control Changes & Financials

Ticker: ZTS · Form: 8-K · Filed: 2024-11-12T00:00:00.000Z

Sentiment: neutral

Topics: control-change, financials, corporate-event

TL;DR

Zoetis filed an 8-K on Nov 11, 2024, reporting control changes and financial docs.

AI Summary

On November 11, 2024, Zoetis Inc. filed an 8-K report detailing changes in control and other events. The filing includes financial statements and exhibits, with the company's principal executive offices located at 10 Sylvan Way, Parsippany, New Jersey.

Why It Matters

This filing signals potential shifts in the ownership or control structure of Zoetis Inc., which could impact its strategic direction and shareholder value.

Risk Assessment

Risk Level: medium — Changes in control can introduce uncertainty regarding future strategy and management, potentially affecting stock performance.

Key Numbers

Key Players & Entities

FAQ

What specific 'Changes in Control' are reported in this 8-K filing for Zoetis Inc.?

The provided text indicates that 'Changes in Control of Registrant' is an item reported, but the specific details of these changes are not elaborated in this excerpt.

When was the earliest event reported in this Form 8-K filing?

The earliest event reported is November 11, 2024, which is also the date of the report.

What is the principal business address of Zoetis Inc. as stated in the filing?

The principal executive offices are located at 10 Sylvan Way, Parsippany, New Jersey 07054.

What is the SIC code for Zoetis Inc.?

The Standard Industrial Classification (SIC) code for Zoetis Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Does this filing indicate any 'Other Events' for Zoetis Inc.?

Yes, the filing explicitly lists 'Other Events' as an item of information being reported.

From the Filing

0001555280-24-000335.txt : 20241112 0001555280-24-000335.hdr.sgml : 20241112 20241112062728 ACCESSION NUMBER: 0001555280-24-000335 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241111 ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 241443026 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20241111.htm 8-K zts-20241111 0001555280 false 0001555280 2024-11-11 2024-11-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 11, 2024 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way Parsippany New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 11, 2024, Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, informed Zoetis Inc. (the “Company”) of her decision to leave the Company in early 2025 to pursue an external opportunity. Ms. Mamilli will continue as an employee of the Company until her departure. As a result of Ms. Mamilli’s planned de

View on Read The Filing